Last edition
News about "Bristol Myers Squibb"
Chai Discovery Collaborates with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery
Chai Discovery and Bristol Myers Squibb partner to advance Artificial Intelligence (AI)-driven antibody discovery, leveraging Chai’s molecular folding and design models to identify antibody candidates.
Bristol Myers Squibb | 21/08/2026 | By News Bureau
US FDA Grants Accelerated Approval to BMS' ZENBEXUS for Multiple Myeloma
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) ZENBEXUS, a first-in-class CELMoD therapy combined with daratumumab and dexamethasone for multiple myeloma.
Bristol Myers Squibb | 14/08/2026 | By News Bureau
Harbour BioMed and Sinopharm Partner to Advance Research and Development
Harbour BioMed and Sinopharm have partnered to establish an innovation Research and Development (R&D) consortium focused on biologics for oncology and immune-mediated diseases.
Bristol Myers Squibb | 28/07/2026 | By News Bureau
Bristol Myers Squibb Partners with NVIDIA to Build AI Factory
Bristol Myers Squibb and NVIDIA are building an Artificial Intelligence (AI) factory to accelerate drug discovery using advanced AI infrastructure and proprietary life sciences models.
Bristol Myers Squibb | 22/07/2026 | By News Bureau
Bristol Myers Squibb Secures FDA Priority Review for Camzyos
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s supplemental New Drug Application (NDA) for Priority Review (PR) of Camzyos (mavacamten) to treat adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Bristol Myers Squibb | 02/06/2026 | By News Bureau | 159
Bristol Myers Squibb reported Phase 3 SUCCESSOR-2 results showing that mezigdomide reduced the risk of disease progression or death by more than 50% versus standard of care in relapsed or refractory multiple myeloma, marking the first successful Phase 3 CELMoD trial presented at ASCO 2026.
Bristol Myers Squibb | 30/05/2026 | By News Bureau | 106
Tempus AI Expands Strategic Partnership with Bristol Myers Squibb
Tempus AI expands its collaboration with Bristol Myers Squibb to use Artificial Intelligence (AI) and real-world data for optimising oncology and neuroscience clinical trials and improving regulatory success rates.
Bristol Myers Squibb | 15/05/2026 | By News Bureau | 323
Bristol Myers Squibb and Hengrui Pharma collaborated to jointly develop 13 early-stage programmes across oncology, haematology and immunology, with a potential deal value of up to USD 15.2 billion.
Bristol Myers Squibb | 13/05/2026 | By News Bureau | 142
Bristol Myers Squibb Secures EC Approval for Sotyktu in Psoriatic Arthritis
Bristol Myers Squibb receives European Commission (EC) approval for Sotyktu to treat active psoriatic arthritis in adults, marking the EU’s first approved TYK2 inhibitor for this indication.
Bristol Myers Squibb | 12/05/2026 | By News Bureau | 184
Atrium Therapeutics receives a USD 15 million milestone payment from Bristol Myers Squibb under a global collaboration to develop innovative RNA-based therapies for cardiovascular diseases.
Bristol Myers Squibb | 24/04/2026 | By News Bureau | 127
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy